YAP/TAZ Signaling and Resistance to Cancer Therapy
- PMID: 31174841
- PMCID: PMC6557283
- DOI: 10.1016/j.trecan.2019.02.010
YAP/TAZ Signaling and Resistance to Cancer Therapy
Abstract
Drug resistance is a major challenge in cancer treatment. Emerging evidence indicates that deregulation of YAP/TAZ signaling may be a major mechanism of intrinsic and acquired resistance to various targeted and chemotherapies. Moreover, YAP/TAZ-mediated expression of PD-L1 and multiple cytokines is pivotal for tumor immune evasion. While direct inhibitors of YAP/TAZ are still under development, FDA-approved drugs that indirectly block YAP/TAZ activation or critical downstream targets of YAP/TAZ have shown promise in the clinic in reducing therapy resistance. Finally, BET inhibitors, which reportedly block YAP/TAZ-mediated transcription, present another potential venue to overcome YAP/TAZ-induced drug resistance.
Keywords: Cancer therapy resistance; Hippo pathway; TAZ; YAP.
Copyright © 2019 Elsevier Inc. All rights reserved.
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6557283/bin/nihms-1525527-f0001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6557283/bin/nihms-1525527-f0002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6557283/bin/nihms-1525527-f0003.gif)
Similar articles
-
Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy.Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188341. doi: 10.1016/j.bbcan.2020.188341. Epub 2020 Jan 10. Biochim Biophys Acta Rev Cancer. 2020. PMID: 31931113 Review.
-
YAP/TAZ for cancer therapy: opportunities and challenges (review).Int J Oncol. 2015 Apr;46(4):1444-52. doi: 10.3892/ijo.2015.2877. Epub 2015 Feb 5. Int J Oncol. 2015. PMID: 25652178 Review.
-
A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy.Theranostics. 2020 Feb 18;10(8):3622-3635. doi: 10.7150/thno.40889. eCollection 2020. Theranostics. 2020. PMID: 32206112 Free PMC article. Review.
-
The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.Cancer Res. 2018 Mar 15;78(6):1457-1470. doi: 10.1158/0008-5472.CAN-17-3139. Epub 2018 Jan 16. Cancer Res. 2018. PMID: 29339539
-
Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.Expert Opin Ther Pat. 2018 Dec;28(12):867-873. doi: 10.1080/13543776.2018.1549226. Epub 2018 Dec 2. Expert Opin Ther Pat. 2018. PMID: 30482112 Review.
Cited by
-
Low concentrations of saracatinib promote definitive endoderm differentiation through inhibition of FAK-YAP signaling axis.Cell Commun Signal. 2024 May 30;22(1):300. doi: 10.1186/s12964-024-01679-7. Cell Commun Signal. 2024. PMID: 38816763 Free PMC article.
-
YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.Gastric Cancer. 2024 Jul;27(4):785-801. doi: 10.1007/s10120-024-01508-3. Epub 2024 May 23. Gastric Cancer. 2024. PMID: 38782859 Free PMC article.
-
Bcl-2 dependent modulation of Hippo pathway in cancer cells.Cell Commun Signal. 2024 May 16;22(1):277. doi: 10.1186/s12964-024-01647-1. Cell Commun Signal. 2024. PMID: 38755629 Free PMC article.
-
The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.BMC Cancer. 2024 May 14;24(1):587. doi: 10.1186/s12885-024-12316-4. BMC Cancer. 2024. PMID: 38741073 Free PMC article.
-
Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy.Mol Metab. 2024 Jun;84:101952. doi: 10.1016/j.molmet.2024.101952. Epub 2024 May 3. Mol Metab. 2024. PMID: 38705513 Free PMC article. Review.
References
-
- Society AC (2018) Cancer Facts & Figures 2018. Am. Cancer Soc DOI: 10.1182/blood-2015-12-687814 - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials